deltatrials
Completed PHASE2 NCT00006682

Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer

An Open-Label Phase II Study of Navelbine (Vinorelbine Tartrate) and Taxotere (Docetaxel) as First-Line Therapy for Metastatic Breast Cancer

Sponsor: Medstar Health Research Institute

Conditions Breast Cancer
Interventions docetaxel vinorelbine ditartrate
Updated 7 times since 2017 Last updated: Aug 12, 2020 Started: Feb 29, 2000 Primary completion: Jan 22, 2002 Completion: Jan 22, 2002

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Medstar Health Research Institute and has accumulated 7 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Unknown Status → Completed

▶ Show 2 earlier versions

  1. Jun 2018 — Sep 2020 [monthly]

    Unknown Status PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medstar Health Research Institute
Data source: Medstar Health Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Washington D.C., United States